FFW
JAZZ icon

Fusion Family Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fusion Family Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-54
Closed -$6K – 371
2016
Q4 		$6K Buy
+54
New +$6.01K ﹤0.01% 291

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Fusion Family Wealth's JAZZ Position: Q1 2017 in Review

Fusion Family Wealth sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2017, closing a stake of 54 shares — an estimated $6K sold.

Fusion Family Wealth first reported a position in JAZZ in Q4 2016 and held it in 1 quarter. The position peaked at $6K in Q4 2016. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

  • Fusion Family Wealth reported no remaining Jazz Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Fusion Family Wealth sold 54 Jazz Pharmaceuticals shares in Q1 2017, an estimated $6K.
  • Fusion Family Wealth first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Fusion Family Wealth's Jazz Pharmaceuticals position peaked at $6K in Q4 2016.
  • 306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on Fusion Family Wealth's 13F filing for Q1 2017, filed 8 May 2017.